Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022 - Summary - MDSpire

Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

  • By

  • John A. Snowden

  • Isabel Sánchez-Ortega

  • Selim Corbacioglu

  • Grzegorz W. Basak

  • Christian Chabannon

  • Rafael de la Camara

  • Harry Dolstra

  • Rafael F. Duarte

  • Bertram Glass

  • Raffaella Greco

  • Arjan C. Lankester

  • Mohamad Mohty

  • Bénédicte Neven

  • Régis Peffault de Latour

  • Paolo Pedrazzoli

  • Zinaida Peric

  • Ibrahim Yakoub-Agha

  • Anna Sureda

  • Nicolaus Kröger

  • May 19, 2022

  • 0 min

Share

Objective:

To provide guidance on haematopoietic cell transplantation (HCT) indications based on clinical practice in EBMT countries, specifically.

Key Findings:
  • HCT categorization includes autologous, syngeneic, and allogeneic transplants.
  • Recent developments in haploidentical HCT show improved outcomes with post-transplant cyclophosphamide.
  • Transplant decisions should integrate clinical evidence, local expertise, and patient preferences.
Interpretation:

The recommendations aim to harmonize HCT practices across Europe while considering evolving evidence and the impact of COVID-19.

Limitations:
  • Recommendations are not based on a formal systematic review.
  • The full impact of COVID-19 on HCT outcomes is still being assessed, and evidence is evolving.
Conclusion:

The guidance serves as a framework for HCT indications, emphasizing the need for individualized patient care and MDT involvement in decision-making.

Original Source(s)

Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

  • by John A. Snowden, Isabel Sánchez-Ortega, Selim Corbacioglu, Grzegorz W. Basak, Christian Chabannon, Rafael de la Camara, Harry Dolstra, Rafael F. Duarte, Bertram Glass, Raffaella Greco, Arjan C. Lankester, Mohamad Mohty, Bénédicte Neven, Régis Peffault de Latour, Paolo Pedrazzoli, Zinaida Peric, Ibrahim Yakoub-Agha, Anna Sureda, Nicolaus Kröger

  • May 19, 2022

Related Content

CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine

Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders

New Clues in Hodgkin Lymphoma Biology

Transcriptome analysis highlights diagnostic targets and immune evasion pathways

  • May 14, 2026

  • 2 min